Cannabis Expansion vs Shareholder Value: What Five Years of SEC Filings Reveal

Rolando García at IgniteIt did the homework most cannabis boards skip. He pulled five years of SEC filings from six major operators and asked a simple question: did all that expansion spending actually create value for shareholders? The answer is uncomfortable, and every operator planning the next buildout should read it twice.

The six companies financed growth in completely different ways between fiscal 2021 and 2025. Some generated real cash. Some bought growth with debt and stock. Some are still waiting for the bill to arrive. Here is what the filings show, and what it means for your next capital decision.

The Green Thumb Benchmark, and What It Hides

Green Thumb Industries is the industry’s gold standard on paper. The company generated about $1.006 billion in operating cash across 2021 through 2025 while spending $748.6 million on property and equipment. It reported $114.2 million in net income for 2025, its sixth consecutive profitable year, with 113 retail locations open at year end.

Look closer and the headline softens. Operating income fell from $224.4 million to $137.7 million in 2025. Net income only rose because of a $125.9 million noncash gain on warrants in another company. The company also paid far less tax than it recorded, and the difference accounts for nearly $98 million of the operating cash increase. Strip that out and the surplus is real but much smaller.

My operator read: never let a consolidated number do your thinking. A group surplus mixes mature stores throwing off cash with newer facilities that have not paid back their cost. The number your board should demand is cash contribution per facility, net of maintenance spending. No annual report will calculate it for you.

Verano: The Acquisition Bill Comes Due

Verano lost money in every year from 2021 to 2025, including a $257.9 million net loss in 2025, its fifth straight annual loss. Over the same period it generated about $552 million in operating cash, spent $437 million on property and equipment, and poured $460.4 million into acquisitions. Growth consumed roughly $345 million more cash than the business produced.

Then came the impairments. Charges against goodwill, intangibles, and assets totaled about $569 million across 2023 through 2025. That is the company telling you, in accounting language, that what it bought is worth less than what it paid.

Here is the test García proposes, and it is the right one: measure what each acquisition returned in cash against the full consideration paid, counting stock and seller notes alongside the wire transfer. Adding impairment charges back into an adjusted earnings figure does not return the cash. The cash is gone.

Glass House: Building Ahead of the Cash

Glass House generated about $2 million in cumulative operating cash between 2021 and 2025 and spent $186 million on property and equipment. Net financing inflows of $208.3 million covered the gap, most of it raised back in 2021. Each greenhouse phase committed capital before the previous phase had a full operating record.

In 2025, with more capacity in place than ever, revenue fell from $200.9 million to $182 million and gross profit dropped from $97.4 million to $77 million. Bigger facilities do lower cost per pound. Whether that pays depends on realized prices, yields, and utilization, and in 2025 the math went the wrong way.

The lesson for anyone building cultivation now: your funding has to reach past commissioning, through harvest, sale, and collection, with interest paid the whole way. Phasing helps only if you finance each phase through commercial operation.

The 280E Cash Mirage

This is the section that should change how you benchmark. Trulieve generated $272.8 million in operating cash in 2025 while carrying a $668.4 million uncertain tax position, most of it tied to its claim that Section 280E does not block ordinary business deductions. Income taxes paid fell from $178.7 million in 2021 to $1.5 million in 2025. Remove the 2025 tax accrual and operating cash was about $50 million, below the $60.5 million spent on property, equipment, and software.

Read that again. A meaningful share of the “cash generation” the market admires is tax the company recorded but has not paid. Rescheduling may resolve that exposure, reduce it, or leave it standing, and nobody can tell you when it settles.

So measure your own cash generation against these operators net of unpaid tax accruals. Otherwise you are comparing your business to a benchmark that is partly a loan from the IRS.

Canopy: Five Years of Shrinking

Canopy Growth spent the period going the other direction. Operations used about C$2.017 billion across fiscal 2021 through 2025. Property and equipment purchases fell from C$164.5 million to C$10.8 million as the company sold assets and moved to an asset light model. Lower investment preserves liquidity. The open question is whether what remains can generate enough cash to sustain itself.

Sometimes the right expansion decision is contraction. The filings just rarely celebrate it.

The Operator Takeaway

When the next expansion proposal reaches your desk, demand three things. First, the mature business must show cash contribution after maintenance capital, working capital, and the taxes it actually expects to pay. Second, new facilities and acquisitions need separate capital schedules with expected cash returns and funding committed through commercial operation. Third, read the financing account gross, because net inflows hide how much debt was raised and repaid in the same year.

Growth is not a strategy. Funded growth that returns cash above its full cost is a strategy. The filings show how rare the second kind has been.

For more on market milestones, see Trulieve and Curaleaf index inclusion in the S and P and FTSE. For investor sentiment behind the numbers, see the 2026 investor survey on medical cannabis markets.

FAQs

1. 1. What did Rolando García actually study?
He pulled five years of SEC filings from six major cannabis operators, fiscal 2021 through 2025, and asked whether all the expansion spending created real value for shareholders.

2. 2. What is the Green Thumb benchmark, and what does it hide?
Green Thumb generated about $1.006 billion in operating cash against $748.6 million in property spending, but 2025 net income rose on a $125.9 million noncash warrant gain while operating income fell. The board should demand cash contribution per facility instead.

3. 3. How did Verano’s acquisition spree work out?
Verano lost money every year, spent $460.4 million on acquisitions, and growth consumed roughly $345 million more cash than the business produced. Then came $569 million in impairments, the accounting way of saying it overpaid.

4. 4. What is the right test for an acquisition?
Measure what each acquisition returned in cash against the full consideration paid, counting stock and seller notes alongside the wire transfer. Adding impairments back into adjusted earnings does not return the cash.

5. 5. What is the Glass House warning?
It generated about $2 million in cumulative operating cash across five years while spending $186 million on property and equipment, with financing covering the gap. Building ahead of the cash only works if the cash eventually shows up.

Source: Read the full analysis at IgniteIt.